OBJECTIVES: To estimate the cost-effectiveness of Dabigatran compared to Warfarin in non-complicated atrial fibrillation in Colombia. METHODS: We developed a Markov model to represent the health states of atrial fibrillation and its complications;6 health states and 2 transitional states were considered,including disabling and non-disabling stroke, myocardial infarction, pulmonary embolism and death. Major and minor hemorrage were considered transitory in the model. Probabilities were derived from published clinical trials. Resource use was estimated from the Colombian Society of Cardiology guidelines and validated to adjust to usual practice. Direct medical costs were derived from different sources (public and private) and indirect costs (predicted wages lost and transportation costs) were obtained from the most recent National Health Survey. Utilities were obtained from a systematic literature review. Two separate analysis, payer and societal perspective, were performed in a 20-year horizon. Maximum and minimum values ​​of effectiveness and resource use were included in the sensitivity analysis. The results were discounted at 3% annually. RESULTS: After 20 years of follow up, discounted direct medical costs accounted for USD$70,500 for Warfarin and $78,840 and $79,860 for 150mg and 110mg of Dabigatran, respectively. When taking into account indirect costs, Warfarin increased their costs by 13% while Dabigatran costs were increased by 9%. Estimated life years for Dabigatran were higher (9.40 and 9.29 for 150mg and 110mg, respectively) as well as the QALYs (8.48, 8.39) than for Warfarin 9.09 LY and 8.12 QALYs. The calculated ICER  was $23,760 and $34,690 per additional QALY when taking into account direct costs and even lower when considering indirect costs. CONCLUSIONS: In Colombia, the use of Dabigatran for the management of non-complicated atrial fibrilation compared to Warfarin increases years of life and QALYs. Assuming a similar willingnes-to-pay as for other cardiovascular interventions, dabigatran is a cost-effective intervention.